FG-2101: a first-in-class lpxc inhibitor for the treatment of MDR gramnegative urinary tract infections.
Active Definitive Contract Awarded Last action
- Contract number
- 75N93022C00060
- Awardee
-
Blacksmith Medicines, Inc. UEI ZCWKWSWHAJD6
- Awarding agency
-
National Institute of Allergy and Infectious Diseases
National Institutes of Health, Department of Health and Human Services
- Obligated
- $12,961,082
Award facts
- Opportunity
-
- Development of Medical Countermeasures for Biothreat Agents, Antimicrobial-Resistant Infections an Emerging Infectious Diseases Pre-Solicitation · PHS20211 · Posted Feb 8, 2021
- Contract value 63% obligated
-
- $12,961,081.69 Current, with exercised options
- $20,506,235.69 Potential, with all options
- Completion date 96% complete
- Current and potential, with all options
- NAICS code
- 541715 Research and Development in the Physical, Engineering, and Life Sciences (except Nanotechnology and Biotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 30 offers Negotiated Proposal / Quote
- Pricing
- Cost Plus Fixed Fee
- Place of performance
- San Diego, CA 92121, USA
- Legislative mandates
-
- Employment Eligibility Verification (E-Verify) FAR subpart 22.18
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Supplemental Agreement for work within scope | $829,012 | |
| Funding Only Action | $1,154,161 | |
| Other Administrative Action | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $601,356 | |
| Supplemental Agreement for work within scope | $469,430 | |
| Exercise an Option | $1,715,196 | |
| Supplemental Agreement for work within scope | $174,986 | |
| Exercise an Option | $3,304,441 | |
| Supplemental Agreement for work within scope | $0 | |
| Vendor DUNS or Name Change - Non-Novation | $0 | |
| Original award | $4,712,500 |
Show all 16
About this award
The National Institute of Allergy and Infectious Diseases awarded a $20.5 million definitive cost-plus-fixed-fee contract to Blacksmith Medicines, Inc. for development of a first-in-class LPXC inhibitor to treat multidrug-resistant gram-negative urinary tract infections on September 21, 2022, with no set-aside.
The originating Broad Agency Announcement, posted February 8, 2021, sought proposals across three research areas: vaccine candidates, therapeutic products, and sequencing-based diagnostics to develop countermeasures against biothreat agents, antimicrobial-resistant infections, and emerging infectious diseases. This effort falls under the therapeutic development track, estimated at up to $11 million total in awards. Work is performed in San Diego, CA, with an ultimate completion date of December 31, 2026.
Service Contract Inventory reporting shows the contract's actual government-invoiced labor grew from 0.1 FTEs and 105 contractor hours in FY2022 ($12 thousand invoiced) to 5.9 FTEs and 12,282 contractor hours in FY2025 ($3.1 million invoiced). The derived government-paid hourly rate rose from $115.23/hr in FY2022 to $251.43/hr in FY2025. In FY2025, the contract engaged two subcontractors accounting for 76 percent of contractor hours.
Quick answers
Who was awarded contract 75N93022C00060?
75N93022C00060 was awarded to Blacksmith Medicines, Inc. by National Institute of Allergy and Infectious Diseases (National Institutes of Health) on September 21, 2022.
How much is contract 75N93022C00060 worth?
The government has obligated $12,961,082 on 75N93022C00060. Its potential value, with all options, is $20,506,236.
Was contract 75N93022C00060 competed?
The extent of competition for 75N93022C00060 was full and open competition. The government received 30 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award